New scan could reveal if breast cancer drugs are working in days
NCT ID NCT02608216
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests whether a special PET scan using a tracer called FLT can show how breast cancer tumors respond to a combination of two drugs, ribociclib and paclitaxel. The study involves 20 people with metastatic breast cancer that has spread beyond the liver and bone. Researchers will take scans before and during treatment to see if changes in tumor activity can predict whether the therapy is working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib (LEE011) and paclitaxel
What this could lead to
If successful, this imaging method could help doctors quickly tell if a breast cancer treatment is working, potentially guiding more personalized therapy.
What could go wrong
This is a very small, early-phase study focused on imaging, not on proving the treatment works. The results may not apply to all patients or lead to a direct benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104, United States